- Home
- ACHR vs CYTK Comparison
ACHR vs CYTK Comparison
Compare ACHR & CYTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACHR
- CYTK
- Stock Information
- Founded
- ACHR 2018
- CYTK 1997
- Country
- ACHR United States
- CYTK United States
- Employees
- ACHR N/A
- CYTK N/A
- Industry
- ACHR Aerospace
- CYTK Biotechnology: Pharmaceutical Preparations
- Sector
- ACHR Industrials
- CYTK Health Care
- Exchange
- ACHR Nasdaq
- CYTK Nasdaq
- Market Cap
- ACHR 6.4B
- CYTK 5.6B
- IPO Year
- ACHR N/A
- CYTK 2004
- Fundamental
- Price
- ACHR $10.61
- CYTK $37.01
- Analyst Decision
- ACHR Strong Buy
- CYTK Buy
- Analyst Count
- ACHR 8
- CYTK 14
- Target Price
- ACHR $13.13
- CYTK $70.92
- AVG Volume (30 Days)
- ACHR 42.7M
- CYTK 1.5M
- Earning Date
- ACHR 08-07-2025
- CYTK 08-07-2025
- Dividend Yield
- ACHR N/A
- CYTK N/A
- EPS Growth
- ACHR N/A
- CYTK N/A
- EPS
- ACHR N/A
- CYTK N/A
- Revenue
- ACHR N/A
- CYTK $19,218,000.00
- Revenue This Year
- ACHR N/A
- CYTK $34.81
- Revenue Next Year
- ACHR N/A
- CYTK $643.79
- P/E Ratio
- ACHR N/A
- CYTK N/A
- Revenue Growth
- ACHR N/A
- CYTK 412.21
- 52 Week Low
- ACHR $2.82
- CYTK $29.31
- 52 Week High
- ACHR $13.92
- CYTK $61.38
- Technical
- Relative Strength Index (RSI)
- ACHR 53.08
- CYTK 65.31
- Support Level
- ACHR $9.76
- CYTK $33.07
- Resistance Level
- ACHR $11.06
- CYTK $36.99
- Average True Range (ATR)
- ACHR 0.58
- CYTK 1.32
- MACD
- ACHR 0.02
- CYTK 0.44
- Stochastic Oscillator
- ACHR 63.81
- CYTK 99.11
About ACHR Archer Aviation Inc.
Archer Aviation Inc advances the benefits of sustainable air mobility. The company is engaged in designing and developing a fully electric vertical takeoff and landing eVTOL aircraft for use in UAM networks. It is creating an electric airline that moves people throughout cities in a quick, safe, sustainable, and cost-effective manner.
About CYTK Cytokinetics Incorporated
Cytokinetics Inc is a biotechnology company that develops muscle biology-driven treatments for diseases characterized by reduced muscle function, muscle weakness, and fatigue. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.